Figure 1From: Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial (A) PFS and (B) TTNT by treatment arm in patients with high-risk FL. Back to article page